[Skip to Content]
[Skip to Content Landing]
Other Articles
September 9, 1950

CLINICAL STUDY OF PREVENTION OF ERYTHROBLASTOSIS WITH Rh HAPTEN

Author Affiliations

Chicago

From the Michael Reese Research Foundation.

JAMA. 1950;144(2):88-92. doi:10.1001/jama.1950.02920020008003
Abstract

Several investigators1 have attempted the extraction of the essential Rh fraction which is undoubtedly present in human Rh-positive erythrocytes. More recently, Carter2 prepared an extract, called it Rh hapten and claimed the following characteristics for such material: (a) inability to generate specific anti-Rh antibodies when injected in vivo by itself; (b) specific neutralization of anti-Rh antibodies in vitro; (c) specific neutralization of anti-Rh antibodies in vivo, i. e., desensitization; (d) clinical value in preventing development of erythroblastosis in pregnant women, and (e) clinical value in treatment of erythroblastotic children. Any substance with the aforementioned characteristics may be called a hapten in accordance with Landsteiner's definition3 for substances incapable of generating specific antibodies in vivo but capable of neutralizing specific antibodies in vitro. A potent Rh hapten might have value clinically if it could "desensitize" pregnant sensitized women who would otherwise have erythroblastotic babies and thus permit the

×